Sugi Predict

Sugi Predict / Compounds / Pyrophosphoric Acid

Pyrophosphoric Acid

Pyrophosphoric Acid

SCHEMBL490709

CCCCN(CCCC)CCCC.CCCCN(CCCC)CCCC.CCCCN(CCCC)CCCC.O=P(O)(O)OP(=O)(O)O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 1/20 0.47
▸ MMP2 P08253 1/20 0.47
▸ MMP3 P08254 1/20 0.47
▸ MMP8 P22894 1/20 0.47
▸ FDPS P14324 2/20 0.46
▸ BLM P54132 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ LPAR3 Q9UBY5 6/20 0.43
▸ LPAR2 Q9HBW0 3/20 0.43
▸ LPAR1 Q92633 2/20 0.43
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ SMPD1 P17405 4/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ S1PR2 O95136 1/20 0.38
▸ S1PR1 P21453 1/20 0.38
▸ S1PR3 Q99500 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrophosphoric Acid SCHEMBL73401 1.00 MMP1 (0.47) MMP1MMP2MMP3MMP8FDPS
Pyrophosphoric Acid SCHEMBL288516 1.00 MMP1 (0.47) MMP1MMP2MMP3MMP8FDPS
Pyrophosphoric Acid SCHEMBL73402 1.00 MMP1 (0.47) MMP1MMP2MMP3MMP8FDPS
Pyrophosphoric Acid SCHEMBL28344128 0.93 LPAR3 (0.47) MMP1MMP2MMP3MMP8FDPS
Triphosphate SCHEMBL5052601 0.91 MMP1 (0.44) MMP1MMP2MMP3MMP8FDPS
Pyrophosphoric Acid SCHEMBL9547118 0.91 LPAR3 (0.50) FDPSBLMTDP1LPAR3LPAR2
Pyrophosphoric Acid SCHEMBL9547107 0.91 LPAR3 (0.50) FDPSBLMTDP1LPAR3LPAR2
Triphosphate SCHEMBL5052598 0.91 MMP1 (0.44) MMP1MMP2MMP3MMP8FDPS
Pyrophosphoric Acid SCHEMBL28321370 0.89 MMP1 (0.39) MMP1MMP2MMP3MMP8FDPS
SCHEMBL4845792 0.88 MMP1 (0.41) MMP1MMP2MMP3MMP8FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9035041-B2 Process for triphosphate oligonucleotide synthesis ALNYLAM PHARMACEUTICALS, INC. (US) 2015-05-19 — — US claimed
US-20120220761-A1 PROCESS FOR TRIPHOSPHATE OLIGONUCLEOTIDE SYNTHESIS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-08-30 — — US claimed
WO-2011028218-A1 PROCESS FOR TRIPHOSPHATE OLIGONUCLEOTIDE SYNTHESIS ALNYLAM PHARMACEUTICALS, INC. (US) 2011-03-10 — — WO claimed
US-20040115665-A1 Method for base sequencing and biologically active nucleic acids RIKEN (JP) 2004-06-17 — — US claimed
JP-2004514440-A — — 2004-05-20 — — JP claimed
EP-1348035-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS Riken (JP) 2003-10-01 — — EP claimed
WO-2002044195-A2 METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS RIKEN (JP) 2002-06-06 — — WO claimed
WO-2023086557-A1 NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS EMORY UNIVERSITY (US) 2023-05-19 — — WO disclosed
US-9376460-B2 Method of polyphosphate synthesis INSTYTUT CHEMII BIOORGANICZNEJ POLSKIEJ AKADEMII NAUK (PL) 2016-06-28 — — US disclosed
US-20150203524-A1 NEW METHOD OF POLYPHOSPHATE SYNTHESIS INSTYTUT CHEMII BIOORGANICZNEJ POLSKIEJ AKADEMII NAUK (PL) 2015-07-23 — — US disclosed
EP-2880044-A1 NEW METHOD OF POLYPHOSPHATE SYNTHESIS Instytut Chemii Bioorganicznej Polskiej Akademii Nauk (PL) 2015-06-10 — — EP disclosed
US-9035041-B2 Process for triphosphate oligonucleotide synthesis ALNYLAM PHARMACEUTICALS, INC. (US) 2015-05-19 — — US disclosed
US-8921124-B2 Pyrazole-based cyanine dye WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-12-30 — — US disclosed
US-5242796-A Fluorescent xanthene dye E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-09-07 — — US disclosed
US-5151507-A Alkynylamino-nucleotides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-09-29 — — US disclosed
US-5102785-A Cleaving to produce DNA fragment which are then end labeled with reporter, again cleaved to produce short fragment, separatiion; analysis E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-04-07 — — US disclosed
EP-0369360-A2 Differentiation of nucleic acid segments on the basis of nucleotide differences E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-05-23 — — EP disclosed
US-4879214-A Differentiation of nucleic acid segments on the basis of nucleotide differences E. I. DU PONT DE NEMOURS AND COMPANY (US) 1989-11-07 — — US disclosed
EP-0309969-A2 Method of gene mapping E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-04-05 — — EP disclosed
EP-0252683-A2 Process and reagents for DNA sequence analysis E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203524-A1 NEW METHOD OF POLYPHOSPHATE SYNTHESIS PNP, PNKP, RNGTT MMP1 2173/4885MMP2 2847/4885MMP3 3773/4885
US-20120220761-A1 PROCESS FOR TRIPHOSPHATE OLIGONUCLEOTIDE SYNTHESIS DUT, DTYMK, ITPA MMP1 3476/4885MMP2 4022/4885MMP3 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.